INTERSTITIAL LUNG DISEASE AND DIFFUSE ALVEOLAR HEMORRHAGE IN THE PRESENCE OF FAM-TRASTUZUMAB DERUXTECAN-NXKI (ENHERTU) FOR STAGE IV BREAST CANCER

被引:0
|
作者
Perez, Hector I. Roman
Sesemann, Lauren
Zero, Natalia
Kregor, Alexandria Clarke
Park, Yoonho
Coughlin, Colin
机构
关键词
D O I
10.1016/j.chest.2023.07.2220
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
引用
收藏
页码:3416A / 3417A
页数:2
相关论文
共 25 条
  • [21] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [22] Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer
    Rugo, Hope S.
    Crossno, Christine L.
    Gesthalter, Yaron B.
    Kelley, Kristen
    Moore, Heather B.
    Rimawi, Mothaffar F.
    Westbrook, Kelly E.
    Buys, Saundra S.
    JCO ONCOLOGY PRACTICE, 2023, 19 (08) : 539 - +
  • [23] Real world data on Trastuzumab Deruxtecan (T-DXd) induced Interstitial Lung disease (ILD) in HER2 positive metastatic breast cancer patients at the Kent Oncology Centre
    Mohammed, S.
    Moss, C.
    Harper-Wynne, C.
    CLINICAL ONCOLOGY, 2025, 38
  • [24] Trastuzumab Deruxtecan (T-DXd)-associated interstitial lung disease (ILD) in a large real- world French cohort of patients with HER2-driven breast cancer and other malignancies
    Elu, Lana
    Canellas, Anthony
    Du Rusquec, Pauline
    Benderra, Marc Antoine
    Drouin, Leonor
    Cojean-Zelek, Isabelle
    Vozy, Aurore
    Assaf, Elias
    Benmaziane, Asmahane
    Medioni, Jacques
    Cohen, Romain
    Zelek, Laurent
    Wislez, Marie
    Gligorov, Jacques
    Brillet, Pierre Yves
    Girard, Nicolas
    Bihan, Kevin
    Cadranel, Jacques
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64